248 related articles for article (PubMed ID: 34559464)
1. Association between dipeptidyl peptidase-4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5-year population-based cohort study using the Japanese National Database.
Kuwata H; Nishioka Y; Noda T; Kubo S; Myojin T; Higashino T; Takahashi Y; Ishii H; Imamura T
J Diabetes Investig; 2022 Mar; 13(3):460-467. PubMed ID: 34559464
[TBL] [Abstract][Full Text] [Related]
2. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
Sugiyama S; Yamamoto T; Aoyama Y
J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
Front Immunol; 2022; 13():843480. PubMed ID: 35309321
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis.
Guo W; Rathi S; Marquez J; Smith H; Kuruvilla A; Tonnesen MG; Salvemini JN
Arch Dermatol Res; 2023 Oct; 315(8):2207-2213. PubMed ID: 36867222
[TBL] [Abstract][Full Text] [Related]
6. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
Kridin K; Bergman R
JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
[TBL] [Abstract][Full Text] [Related]
7. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
Lee SG; Lee HJ; Yoon MS; Kim DH
JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials.
Yang W; Cai X; Zhang S; Han X; Ji L
Diabetes Metab Res Rev; 2021 Mar; 37(3):e3391. PubMed ID: 32741073
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
[TBL] [Abstract][Full Text] [Related]
11. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.
Douros A; Rouette J; Yin H; Yu OHY; Filion KB; Azoulay L
Diabetes Care; 2019 Aug; 42(8):1496-1503. PubMed ID: 31182489
[TBL] [Abstract][Full Text] [Related]
13. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
14. Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan.
Kubota S; Haraguchi T; Kuwata H; Seino Y; Murotani K; Tajima T; Terashima G; Kaneko M; Takahashi Y; Takao K; Kato T; Shide K; Imai S; Suzuki A; Terauchi Y; Yamada Y; Seino Y; Yabe D
J Diabetes Investig; 2023 Jan; 14(1):67-74. PubMed ID: 36281720
[TBL] [Abstract][Full Text] [Related]
15. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Tasanen K; Varpuluoma O; Nishie W
Front Immunol; 2019; 10():1238. PubMed ID: 31275298
[TBL] [Abstract][Full Text] [Related]
17. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
Karthik S; Joseph PE; Babu T
J Postgrad Med; 2019; 65(4):244-246. PubMed ID: 31535624
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
Kawaguchi Y; Shimauchi R; Nishibori N; Kawashima K; Oshitani S; Fujiya A; Shibata T; Ohashi N; Izumi K; Nishie W; Shimizu H; Arima H; Sobajima H
J Diabetes Investig; 2019 Mar; 10(2):392-398. PubMed ID: 29920976
[TBL] [Abstract][Full Text] [Related]
20. Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study.
Magdaleno-Tapial J; Valenzuela-Oñate C; Esteban Hurtado Á; Ortiz-Salvador JM; Subiabre-Ferrer D; Ferrer-Guillén B; Giacaman-von der Weth M; García-Legaz Martínez M; Martínez-Domenech Á; Hernández-Bel P; Esteve-Martínez A; Pérez-Pastor G; Zaragoza-Ninet V; García-Rabasco A; Martínez-Aparicio A; Sánchez-Carazo JL; Pérez-Ferriols A; Alegre-de Miquel V
Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):249-253. PubMed ID: 31864538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
